Singapore markets closed
Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,803.59 +1,363.92 (+2.08%) CMC Crypto 200
1,363.72 -10.12 (-0.74%)
GILD Nov 2024 80.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:26AM EDT. Market open.
| Previous close | 0.8500 |
| Open | 0.8000 |
| Bid | 0.1500 |
| Ask | 1.0100 |
| Strike | 80.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.8000 - 0.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 480 |
Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
Yahoo FinanceOne stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
© 2024 Yahoo. All rights reserved.